Emerging Novel Injectable Agents will Reduce Botox Market Share

High cost of injectable therapies will limit overall uptake in benign prostatic hyperplasia.

Decision Resources finds that, owing to longer than expected clinical development as well as competition from emerging novel injectable agents for the treatment of benign prostatic hyperplasia, Allergan's Botox will garner less market share than had been previously forecasted in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor 2010 finding from the topic entitled Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms reveals that the combined uptake of Nymox's NX-1207 and Protox Therapeutics' PRX-302, which are expected to launch in the United States and in Europe by 2014, will reduce Botox's expected market share in 2018 by more than half than was previously forecasted. However, the high cost of all three of these novel injectable therapies will limit their overall uptake in a market that is saturated with effective, well-established oral agents.

"We anticipate that novel injectable therapies will have only a small impact on the overall benign prostatic hyperplasia market as few patients will be switched from the oral medications they are currently receiving," said Decision Resources Analyst Benjamin Guikema, PhD. "Although Botox benefits from physician familiarity and brand recognition, we expect that injectable therapies for benign prostatic hyperplasia will be reserved for a niche group of patients with the most severe forms of the disease who would otherwise require minimally invasive treatments or surgery."

The Pharmacor 2010 findings also reveal that, through 2018 in the benign prostatic hyperplasia market, no agents from the gonadotropin-releasing hormone antagonist drug class will launch, following last month's discontinuation of AEterna Zentaris/Spectrum/Nippon Kayaku's ozarelix.

On January 27, Spectrum Pharmaceuticals announced that it would end clinical development of ozarelix, owing to disappointing Phase II clinical trial results.

Source: Decision Resources